

A Unique Indolo-[1,7]naphthyridine Alkaloid from *Incarvillea mairei* var. *grandiflora* (WEHRH.) GRIERSON

by Yun-Heng Shen^{a)}, Yong-Qing Su^{a)b)}, Jun-Mian Tian^{a)}, Sheng Lin^{a)}, Hui-Liang Li^{a)}, Jian Tang^{a)}, and Wei-Dong Zhang^{*a)c)}

^{a)} Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, P. R. China (phone/fax: +86-21-81871244; e-mail: wdzhangy@hotmail.com)

^{b)} No. 123rd Hospital of PLA, Bengbu 233015, P. R. China

^{c)} School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200030, P. R. China

A novel alkaloid with a unique indolo-[1,7]naphthyridine nucleus, incargranine B, was isolated from the whole plant of *Incarvillea mairei* var. *grandiflora* (WEHRH.) GRIERSON. Its structure was determined by means of spectroscopic methods.

Introduction. – *Incarvillea mairei* var. *grandiflora* (WEHRH.) GRIERSON (Bignoniaceae), mainly native to the mountains of Yunnan, Sichuan, and Qinghai provinces [1][2], is a member of the genus *Incarvillea*. Several structurally diverse actinidine-type monoterpene alkaloids with strong antinociceptive activity have been isolated from the genus *Incarvillea* [3–13], and attracted more attention due to their biological activities and structural complexities. We have previously reported the isolation and structural elucidation of two new alkaloids, isoincarvilline and incargranine A [14]. Further investigation of this plant led to another structurally unique decahydro-indolo-[1,7]naphthyridine alkaloid, incargranine B (**1**), isolated from the 80% EtOH extract of the whole plant of *I. mairei* var. *grandiflora*. Here, we report the isolation and structure elucidation of incargranine B (**1**; Fig. 1).

Results and Discussion. – The AcOEt extract (350 g) of the 80% EtOH extract of *I. mairei* var. *grandiflora* was chromatographed over silica-gel column with gradient




Fig. 1. Chemical structure of **1**

$\text{CHCl}_3/\text{MeOH}$ (100:0 \rightarrow 0:100) to afford nine fractions 1–9, and *Fraction 9* was further purified by repeated column chromatography over silica gel and *Sephadex LH-20* (MeOH) to provide compound **1** (7 mg).

For incargranine B (**1**; *Fig. 1*), the molecular formula $\text{C}_{36}\text{H}_{50}\text{N}_2\text{O}_{12}$ was established by negative-ion-mode HR-ESI-MS (m/z 701.3282 ($[M - \text{H}]^-$, for $\text{C}_{36}\text{H}_{49}\text{N}_2\text{O}_{12}$; calc. 701.3286)), indicating 13 degrees of unsaturation. The ^1H -NMR spectrum (*Table*) of **1** exhibited the signals of one 1,4-substituted phenyl ($\delta(\text{H})$ 6.59 (*d*, $J = 8.4$, 2 H), 7.09 (*d*, $J = 8.4$, 2 H)), one 1,3,4-substituted phenyl ($\delta(\text{H})$ 7.03 (*d*, $J = 7.9$), 6.85 (*s*), 6.65 (*d*, $J = 7.9$)), and two sugar moieties (two anomeric H-atom signals at $\delta(\text{H})$ 4.31 (*d*, $J = 7.8$) and 4.21 (*d*, $J = 7.8$), and a series of signals between $\delta(\text{H})$ 3.13 and 3.90). The ^{13}C -NMR spectrum of **1** showed signals for 36 C-atoms, attributed to five sp^2 quaternary C-atoms, 20 CH groups (7 sp^2 , 13 sp^3), and 11 sp^3 CH_2 groups. Analysis of the ^1H , ^1H -COSY (*Fig. 2*) and HSQC data together with the 1D-NMR spectra of **1** led to identification of the partial structures **a** (N(1) to C(8)), **b** (C(1') to C(6')), **c** (C(7') to C(8')), **d** (C(1'') to C(6'')), **e** (C(7'') to C(8'')), **f** (C(1''') to C(6''')), and **g** (C(1''''') to C(6'''''))¹ (*Fig. 2*). Further analysis of the HMBC spectrum allowed attribution of the seven partial structures to five substructures: one decahydro-indole-[1,7]naphthyridine moiety, one 2-(4-substituted phenyl)ethanol moiety, one 2-(3,4-disubstituted phenyl)ethanol moiety, and two glucopyranoses ($\delta(\text{C})$ 104.6, 75.3, 78.2, 71.8, 78.1, 63.0, and 104.6, 75.3, 78.2, 71.8, 78.1, 62.9, resp.). Of 13 degrees of unsaturation, two were assigned to the two glucoses, two to the decahydro-1,7-naphthyridine moiety, and eight to the two 2-phenylethanol moieties, thus **1** was inferred to possess another ring. The result suggested the presence of a fused pentacyclic ring system for **1** between decahydro-1,7-naphthyridine moiety and 2-(3,4-disubstituted phenyl)ethanol moiety. The connections of C(8) to C(3'') and N(1) to C(4'') was further confirmed by the HMBC correlations H–C(8)/C(2''), C(3''), and C(4''). The HMBC correlation H–C(8)/C(4') indicated that 2-(4-substituted phenyl)ethanol moiety was located at N(7). In the HMBC spectrum of **1**, the long correlations H–C(1''')/C(8') and H–C(1''''')/C(8'') established the connections of two glucose moieties with two 2-phenylethanol moieties, respectively (*Fig. 2*). Thus, the gross planar structure of incargranine B was assigned as shown in *Figs. 1* and *2*.





Fig. 2. Selected HMBC (H \rightarrow C) and ^1H , ^1H -COSY (\longleftrightarrow) correlations of **1**

¹) Arbitrary atom numbering as indicated in *Fig. 1*. For systematic names, see *Exper. Part*.

Table. ^1H - (600 MHz) and ^{13}C -NMR (150 MHz) Data of **1** (in CD_3OD , J in Hz, δ in ppm). Arbitrary C-atom numbering.

	$\delta(\text{H})$	$\delta(\text{C})$		$\delta(\text{H})$	$\delta(\text{C})$
$\text{CH}_2(2)$	3.64–3.65 (<i>m</i> , H_a), 2.79–2.81 (<i>m</i> , H_b)	49.3	$\text{C}(1'')$ $\text{H}-\text{C}(2'')$	6.85 (<i>s</i>)	130.3 129.1
$\text{CH}_2(3)$	2.05–2.10 (<i>m</i>)	23.9	$\text{C}(3'')$		130.3
$\text{CH}_2(4)$	2.21–2.25 (overlap, H_a), 1.70–1.75 (overlap, H_b)	33.3	$\text{C}(4'')$ $\text{H}-\text{C}(5'')$	6.65 (<i>d</i> , $J=7.9$)	147.2 113.7
$\text{H}-\text{C}(4a)$	2.71–2.75 (overlap)	49.5	$\text{H}-\text{C}(6'')$	7.03 (<i>d</i> , $J=7.9$)	129.0
$\text{CH}_2(5)$	2.21–2.25 (overlap, H_a), 1.70–1.75 (overlap, H_b)	31.7	$\text{CH}_2(7'')$ $\text{CH}_2(8'')$	2.71–2.75 (overlap) 3.86–3.88 (<i>m</i> , H_a), 3.55–3.58 (overlap, H_b)	37.0 72.5
$\text{CH}_2(6)$	3.55–3.58 (overlap, H_a), 3.25–3.26 (<i>m</i> , H_b)	51.0	$\text{H}-\text{C}(1''')$	4.31 (<i>d</i> , $J=7.8$)	104.6
$\text{H}-\text{C}(8)$	4.27 (<i>d</i> , $J=9.0$)	61.7	$\text{H}-\text{C}(2''')$	3.13 (<i>t</i> , $J=7.8$)	75.3
$\text{H}-\text{C}(8a)$	2.34–2.37 (<i>m</i>)	66.7	$\text{H}-\text{C}(3''')$	3.19–3.22 (<i>m</i>)	78.2
$\text{C}(1')$		128.5	$\text{H}-\text{C}(4''')$	3.27–3.29 (overlap)	71.8
$\text{H}-\text{C}(2')$	7.09 (<i>d</i> , $J=8.4$)	130.8	$\text{H}-\text{C}(5''')$	3.31–3.34 (overlap)	78.1
$\text{H}-\text{C}(3')$	6.59 (<i>d</i> , $J=8.4$)	114.8	$\text{CH}_2(6''')$	3.90 (<i>dd</i> , $J=13.2, 9.6$, H_a), 3.62 (<i>dd</i> , $J=13.2, 2.4$, H_b)	63.0
$\text{C}(4')$		149.7	$\text{H}-\text{C}(1''''')$	4.21 (<i>d</i> , $J=7.8$)	104.6
$\text{H}-\text{C}(5')$	6.59 (<i>d</i> , $J=8.4$)	114.8	$\text{H}-\text{C}(2''''')$	3.23 (<i>t</i> , $J=7.8, 8.5$)	75.3
$\text{H}-\text{C}(6')$	7.09 (<i>d</i> , $J=8.4$)	130.8	$\text{H}-\text{C}(3''''')$	3.27–3.29 (overlap)	78.2
$\text{CH}_2(7')$	2.83–2.87 (<i>m</i>)	36.6	$\text{H}-\text{C}(4''''')$	3.27–3.29 (overlap)	71.8
$\text{CH}_2(8')$	4.04–4.07 (<i>m</i> , H_a), 3.69–3.73 (<i>m</i> , H_b)	72.5	$\text{H}-\text{C}(5''''')$ $\text{CH}_2(6''''')$	3.31–3.34 (overlap) 3.72 (<i>dd</i> , $J=13.2, 9.6$, H_a), 3.62 (<i>dd</i> , $J=13.2, 2.4$, H_b)	78.1 62.9

The relative configuration of **1** was deduced from the ROESY spectrum as shown in the computer-generated three-dimensional drawing (Fig. 3). In the ROESY spectrum, no correlations $\text{H}-\text{C}(8)/\text{H}-\text{C}(8a)$ and $\text{H}-\text{C}(4a)/\text{H}-\text{C}(8a)$ were observed, while the presence of the strong correlation $\text{H}-\text{C}(8)/\text{H}-\text{C}(4a)$ suggested that $\text{H}-\text{C}(4a)$,

Fig. 3. Key NOESY correlations of **1**

H–C(8), and H–C(8a) were α -, α -, and β -oriented, respectively. Therefore, the structure of **1** was identified, and named incargranine B.

The structure of **1** represents a new type of alkaloid, namely decahydro-indolo-[1,7]naphthyridine alkaloid.

Experimental Part

General. Column chromatography (CC) was performed on silica gel (200–300 mesh), *H60* (Qingdao Marine Chemical Plant, Qingdao, P. R. China), and *Sephadex LH-20* (Pharmacia Fine Chemicals, Piscataway, NJ, USA). Optical rotation: *Perkin-Elmer 341* digital polarimeter; at 589 nm. ^1H -, ^{13}C -, and 2D-NMR Spectra: *Bruker DRX-500* spectrometer; in CDCl_3 ; δ in ppm rel. to Me_4Si , J in Hz. MS: *Agilent-1100-LC/MSD-Trap* (ESI-MS) and *Agilent Micro-Q-ToF* (HR-ESI-MS) spectrometer; in m/z .

Plant Material. The whole plants of *I. mairei* var. *grandiflora* were collected in Zhongdian County, Yunnan Province, in late October 2006, and authenticated by Prof. *Li-Shan Xie* of Kunming Institute of Botany, Chinese Academy of Sciences. A voucher specimen (No. 2006101020) is deposited with the School of Pharmacy, Second Military Medical University.

Extraction and Isolation. The dried whole plant of *I. mairei* var. *grandiflora* (32.5 kg) was finely pulverized and extracted with 80% EtOH under reflux for three times. The combined extracts were concentrated to a small volume *in vacuo*, then dissolved in 2% HCl, and filtered. The filtrate was adjusted to pH 9–10 by adding NH_4OH and then extracted with CHCl_3 . The remaining aq. layer was neutralized with by 2% HCl to pH 7 and extracted with AcOEt. The AcOEt extract (350 g) was subjected to CC (silica gel; gradient $\text{CHCl}_3/\text{MeOH}$ 100:0 \rightarrow 0:100) to afford *Fractions 1–9*. *Fr. 9* was purified by repeated CC (silica gel and *Sephadex LH-20* (MeOH)) to provide compound **1** (7 mg).

Incargranine B (=2-(4-{rel-(3aR,11bR,11cS)-10-[2-(β -D-Glucopyranosyloxy)ethyl]-2,3,3a,4,5,6,11b,11c-octahydro-1H-indolo[3,2,1-ij][1,7]naphthyridin-1-yl}phenyl)ethyl β -D-Glucopyranoside; **1**). Brown powder. $[\alpha]_D^{20} = -12$ ($c = 0.275$, MeOH). ^1H - and ^{13}C -NMR: *Table*. ESI-MS (neg.): 701 ($[M - \text{H}]^-$), 737 ($[M + \text{Cl}]^-$). HR-ESI-MS (neg.): 701.3282 ($[M - \text{H}]^-$, $\text{C}_{36}\text{H}_{49}\text{N}_2\text{O}_{12}$; calc. 701.3286).

The work was supported by *NCET Foundation*, *NSFC* (30725045), the *Special Program for New Drug Innovation of the Ministry of Science and Technology*, China (2009ZX09311-001, 2008ZX09308-005), *Shanghai Leading Academic Discipline Project* (B906), and in part by the *Scientific Foundation of Shanghai, China* (09DZ1975700, 09DZ1971500).

REFERENCES

- [1] W. C. Wang, 'Flora of China', Science Press, Beijing, 1990, Vol. 69, p. 46.
- [2] K. Xu, Y. L. Liu, H. Hu, *J. Yunnan Agric. Univ.* **2005**, *20*, 559.
- [3] M. Nakamura, Y.-M. Chi, J. Kinjo, W.-M. Yan, T. Nohara, *Phytochemistry* **1999**, *51*, 595.
- [4] Y.-M. Chi, F. Hashimoto, W.-M. Yan, T. Nohara, *Phytochemistry* **1997**, *46*, 763.
- [5] Y.-M. Chi, M. Nakamura, X. Y. Zhao, *Nat. Prod. Res. Dev.* (in Chinese) **2005**, *17*, 362.
- [6] T. F. Ji, X. Z. Fen, *Chin. Tradit. Herb. Drugs* **2002**, *33*, 967.
- [7] M. Nakamura, K. Kido, J. Kinjo, T. Nohara, *Phytochemistry* **2000**, *53*, 253.
- [8] Y.-M. Chi, W.-M. Yan, J. S. Li, *Phytochemistry* **1990**, *29*, 2376.
- [9] Y.-M. Chi, W.-M. Yan, D. C. Chen, N. Hiroshi, I. Yoichi, S. Ushio, *Phytochemistry* **1992**, *31*, 2930.
- [10] Y.-M. Chi, F. Hashimoto, W.-M. Yan, T. Nohara, *Phytochemistry* **1995**, *39*, 1485.
- [11] Y.-M. Chi, F. Hashimoto, W.-M. Yan, T. Nohara, *Phytochemistry* **1995**, *40*, 353.
- [12] Y.-M. Chi, F. Hashimoto, W.-M. Yan, T. Nohara, M. Yamashita, N. Marubayashi, *Chem. Pharm. Bull.* **1997**, *45*, 495.
- [13] M. Nakamura, Y.-M. Chi, W.-M. Yan, Y. Nakasugi, T. Yoshizawa, N. Irino, F. Hashimoto, J. Kinjo, T. Nohara, S. Sakurada, *J. Nat. Prod.* **1999**, *62*, 1293.
- [14] Y.-Q. Su, Y.-H. Shen, S. Lin, J. Tang, J.-M. Tian, X.-H. Liu, W.-D. Zhang, *Helv. Chim. Acta* **2009**, *92*, 165.

Received March 6, 2010